[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"freezing-of-gait-symptoms-in-parkinson-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:freezing-of-gait-symptoms-in-parkinson-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100634673","a-system-to-help-with-freezing-of-gait-in-parkinsons-patients-100634673",false,"NCT07542743","A System to Help With Freezing of Gait in Parkinson's Patients","A Novel Instrument to Address Freezing of Gait in Parkinson's Patients","Inclusion Criteria:\n\n* Confirmed diagnosis of idiopathic Parkinson's Disease\n* Prior identified presence of Freezing of Gait\n* Ability to ambulate;\n* Montreal Cognitive Assessment (MOCA) MOCA questionnaire score \\>=21.\n\nExclusion Criteria:\n\n* Peripheral neuropathy\n* Dementia\n* Severe gait abnormalities not related to Parkinson's Disease.","ALL","21 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if the ParkinSense system, a customizable, multimodal, and adaptable cueing system, can assist with freezing of gait (FOG) in patients with Parkinson's disease. The main question it aims to answer is: is the percent of time spent frozen reduced when using the system compared to not using the system? Participants will be asked to take part in a single-visit laboratory study where they will wear the system in a controlled environment, followed by a two weeks of home use.",[26],"Freezing of Gait Symptoms in Parkinson Disease",[28,29,30],"FOG","Freezing of Gait","Parkinson's Disease","NOT_YET_RECRUITING","2026-04-20",{"date":34,"type":35},"2026-04-21","ACTUAL",{"date":37,"type":20},"2026-06-01",{"date":39,"type":20},"2027-05-31",{"name":41,"class":42},"Barron Associates, Inc.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100617259","phase-3-pharmacologically-modulating-the-noradrenergic-arousal-system-to-reduce-freezing-of-gait-in-parkinsons-disease-a-multi-centre-and-multi-modal-approach-100617259","NCT07316296","Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach","AnTi-FREEZE","Inclusion Criteria:\n\n* Aged 18 years or older;\n* Diagnosis of idiopathic PD according to MDS Diagnostic Criteria;\n* Stabilised on optimal dopaminergic PD treatment for a minimum of four weeks prior to the baseline visit (Visit 1) and for the duration of the trial;\n* Presence of FOG symptoms on a daily basis;\n* Ability to walk for 10-meters unaided in the dopaminergic ON-state;\n* Ability to provide written informed consent in accordance with ICH-GCP and local regulations;\n* Willing and able to undergo all clinical trial assessments.\n\nExclusion Criteria:\n\n* Current and\u002For previous (within 3 months) participation in a clinical trial;\n* Any contra-indications for undergoing MRI-scanning (e.g. claustrophobia or metal parts within the body such as DBS, an infusion pump or a pacemaker);\n* Co-morbidity that significantly impacts ambulation (e.g. orthopaedic or rheumatological ailments);\n* Severe cognitive impairment hampering the ability to comply with the study protocol;\n* Active psychosis that would impact the ability to comply with the study protocol;\n* Severe cardiovascular disorders: severe hypertension (Sustained (Sitting) hypertension of ≥180 mmHg systolic or ≥110 mmHg diastolic, defined by the average of three observations, each at least 3 minutes apart, with the participant having assumed the required position for at least 3 minutes), heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias, long QT interval syndrome (QTc \\> 500ms Bazett-formula) and channelopathies that in the opinion of the study PI would significantly compromise participant safety;\n* Severe cerebrovascular disorders: cerebral aneurysm or recent\u002Fsignificant stroke;\n* Hepatic or renal insufficiency that in the opinion of the Principal Investigator would impact on the ability of the participant to safely participate;\n* Narrow angle glaucoma;\n* (History of) pheochromocytoma;\n* Use of noradrenergic agents;\n* Use of CYP2D6 inhibitors (SSRIs, quinidine, terbinafine);\n* Use of high dose salbutamol (or other beta2 agonists) that in the opinion of the Principal Investigator would impact on the ability of the participant to safely participate;\n* Pregnancy and\u002For breastfeeding;\n* Known hypersensitivity to atomoxetine.","18 Years",{"count":19,"type":20},[54],"PHASE3","The goal of this clinical trial is to learn if the medication atomoxetine can reduce freezing of gait in people with Parkinson's disease. The main questions it aims to answer is:\n\nDoes atomoxetine reduce the frequency or severity of freezing of gait? What role does noradrenaline play in freezing of gait?\n\nResearchers will compare atomoxetine to a placebo to see if atomoxetine can improve freezing of gait in people with Parkinson's disease.\n\nParticipants will:\n\nVisit the study site for measurements Take atomoxetine or placebo Perform walking assessments and undergo MRI Complete questionnaires about anxiety, stress, and quality of life",[57,29,26],"Parkinson's Disease (PD)","RECRUITING","2026-02-24",{"date":61,"type":35},"2026-02-27",{"date":63,"type":35},"2026-01-01",{"date":65,"type":20},"2027-12-31",{"name":67,"class":68},"Radboud University Medical Center","OTHER",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":5},"100578746","turn-it-fog-improving-turning-and-freezing-of-gait-in-people-with-pd-100578746","NCT06815302","TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD","TURN-IT FOG: A Novel Intervention to Improve Turning in People With PD and Freezing of Gait","Inclusion Criteria:\n\n* diagnosis of idiopathic PD from movement disorders neurologist with the United Kingdom Brain Bank criteria of bradykinesia with one or more of the following - rest tremor, rigidity, and balance problems not from visual, vestibular, cerebellar or proprioceptive conditions\n* reporting FOG in the New Freezing of Gait questionnaire (N-FOGQ)\n* Hoehn \\& Yahr stages II-IV\n* ages 50-80 years old\n* cognitive ability sufficient to participate in testing procedures and exercise classes\n* be willing and able to participate in exercise intervention 3x\u002Fweek for 6 weeks\n\nExclusion Criteria:\n\n* Major musculoskeletal or neurological disorders, structural brain disease, epilepsy, acute illness or health history, other than PD, significantly affecting gait and turning (i.e., musculoskeletal disorder, vestibular problem, head injury, stroke, cardiac disease)\n* medical condition or medications that precludes moderate-intensity exercise\n* Montreal Cognitive Assessment (MoCA) ≤21 or inability to follow directions\n* excessive use of alcohol or recreational drugs\n* recent change in medication\n* inability to stand and walk for 2 minutes without an assistive device","50 Years","80 Years",{"count":19,"type":20},[23],"The goals of this clinical trial are to 1) learn how two different rehabilitation interventions for PD can reduce Freezing of Gait (FOG) in people with Parkinson's disease, as assessed by patients, clinicians, and wearable sensors, and 2) to explore whether two different rehabilitation intervention can reduce FOG and improve daily life mobility in people with FOG sufficiently to justify a clinical trial.\n\nParticipants will:\n\n* Be randomly assigned to one of two intervention groups (turning-focused agility exercise or strength-based exercise)\n* Have one-on-one training sessions three times per week for 6 weeks\n* Perform in-lab assessments before beginning and after completing the study intervention\n* Use wearable mobility sensors during daily life to measure their walking and balance",[82,26],"Parkinson Disease","2025-07-24",{"date":85,"type":35},"2025-07-28",{"date":87,"type":35},"2025-06-02",{"date":89,"type":20},"2027-06-30",{"name":91,"class":68},"Oregon Health and Science University"]